Neurona Therapeutics

28 articles about Neurona Therapeutics

• Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)

  12/1/2023

  Neurona Therapeutics announced presentation of positive preliminary clinical data from the first cohort of five subjects in its ongoing open-label, single-arm Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant MTLE.

• Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy

  10/19/2023

  Neurona Therapeutics announced completion of enrollment of the first cohort of five subjects at the starting dose-level in its ongoing open-label, single-arm Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE).

• Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October

  10/10/2023

  Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Jefferies Inaugural Biotech CNS/Neuro Summit at 1:00 pm ET on Thursday, October 12, 2023.

• Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy

  10/5/2023

  Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy.

• Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer

  7/31/2023

  Neurona Therapeutics today announced the appointment of James Stutz, a business and finance executive with over 20 years of experience in the biopharma industry, as chief financial officer (CFO) and chief business officer (CBO).

• Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy

  6/15/2023

  Neurona Therapeutics announced the presentation of new data from the open-label, single arm, starting dose-level of its ongoing Phase I/II clinical trial of a one-time dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy.

• Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting

  4/24/2023

  Neurona Therapeutics announced the presentation of updated clinical data from its ongoing Phase I/II clinical trial of a single dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE).

• Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference

  3/8/2023

  Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15 at 2:00 pm ET.

• Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy

  2/14/2023

  Neurona Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to Neurona’s ongoing Phase I/II clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE) enabling expansion of enrollment to include adults who have dominant-lobe disease, as well as those whose disease is focused in the non-dominant lobe.

• Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting

  12/5/2022

  Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of clinical data from Neurona’s ongoing Phase I/II clinical trial of NRTX-1001 in people with mesial temporal lobe epilepsy (MTLE) as well as supporting preclinical and manufacturing data at the annual meeting of the American Epilepsy Society.

• Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data

  11/21/2022

  Neurona Therapeutics announced that Cory R. Nicholas, Ph.D. was invited to present an overview of Neurona’s regenerative cell therapy technology, proprietary manufacturing process, cell delivery system, and preclinical data supporting its ongoing Phase I/II clinical trial of NRTX-1001 in people with focal epilepsy at the recent ISSCR Boston International Symposium.

• Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

  9/21/2022

  Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the presentation of a clinical case study from the initial dose cohort of the Phase 1/2 first-in-human epilepsy clinical trial of its lead program, NRTX-1001.

• Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting

  6/17/2022

  Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the presentation of investigational new drug (IND)-enabling data that support the company’s lead inhibitory neuronal cell therapy candidate, NRTX-1001, which has entered a first-in-human clinical trial for the treatment of drug-resistant focal epilepsy.

• Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy

  5/26/2022

  Neurona Therapeutics announced that it has been awarded a $7,999,999 grant by the California Institute for Regenerative Medicine to support a dose-escalation Phase 1/2 clinical trial of NRTX-1001, an inhibitory cell therapy that is being evaluated for safety and efficacy in people with drug-resistant mesial temporal lobe epilepsy.

• Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference

  4/4/2022

  Neurona Therapeutics today announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, which is being organized in partnership with the Harvard Stem Cell Institute, on April 11, 2022, at 3:00 PM ET.

• Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy

  4/1/2022

  Neurona Therapeutics announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. NRTX-1001 is being evaluated in a Phase 1/2 clinical trial in people with drug-resistant mesial temporal lobe epilepsy.

• Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  1/5/2022

  Neurona Therapeutics announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, which is being held January 10 -13, 2022.

• Neurona Therapeutics Announces C-Suite Leadership Team

  12/13/2021

  Neurona Therapeutics today announced three promotions within its leadership team.

• Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

  12/3/2021

  Neurona Therapeutics, today announced that Catherine Priest, Ph.D., Neurona’s head of preclinical development, and David Blum, MD., Neurona’s head of clinical development, will present preclinical data that support the company’s recently cleared investigational new drug (IND) application and the initiation of the first-in-human Phase 1/2 clinical trial to evaluate lead asset, NRTX-1001.

• Neurona Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

  11/18/2021

  Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Piper Sandler 33rd Annual Healthcare Conference.